as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹625.0
Change
+10.2 (1.66%)
Open
₹611.8
Prev. Close
₹614.8
Day High
₹629.0
Day Low
₹608.05
Volume Analysis
Traded
201,399
Delivered
126,611
Delivery %
62.87%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹654.26 | ₹641.63 | ₹633.31 | ₹620.68 | ₹612.36 | ₹599.73 | ₹591.41 |
| Fibonacci | ₹641.63 | ₹633.63 | ₹628.68 | ₹620.68 | ₹612.68 | ₹607.73 | ₹599.73 |
| Camarilla | ₹630.76 | ₹628.84 | ₹626.92 | ₹620.68 | ₹623.08 | ₹621.16 | ₹619.24 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-15.64%
1 Week
-2.66%
1 Month
-25.82%
3 Months
-22.4%
6 Months
-19.26%
1 Year
-19.12%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Supriya Lifescience Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 60/100. The strongest factor is Corporate Governance (85/100), while Risk & Volatility (42/100) is the weakest area to weigh before deciding. FII holding has been rising.
TopFund Score — Fundamentals Quality
60/100 — AverageData confidence: 61/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Corporate Governance
Institutional Ownership
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Audio recording of November 6, 2026 earnings call for Q2 and H1 FY2026-27 available on website.
Q2 FY27 revenue Rs 206.30 crore; Ambernath facility commissioned and commercial production began.
Investor Presentation is enclosed for the Results Earnings Call for quarter and half year ended September 30, 2026.
Source: BSE regulatory filings, via Screener.in.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 21.77% | 21.04% | 21.27% | 20.22% | 20.25% | 20.25% | 20.08% | 21.02% | 21.49% | 20.83% | 20.21% | 19.8% |
| Promoters | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% | 68.3% |
| FII | 4.56% | 5.37% | 4.95% | 6.03% | 6.52% | 7.19% | 6.78% | 5.46% | 5.19% | 5.16% | 6.18% | 6.45% |
| DII | 5.39% | 5.3% | 5.48% | 5.45% | 4.93% | 4.26% | 4.86% | 5.22% | 5.0% | 5.7% | 5.3% | 5.47% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Supriya Lifescience Ltd (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 451,075 | 36.7 | 5.05 | 16.0% |
| Divi S Laboratories Ltd | 294,139 | 86.1 | 16.34 | 16.5% |
| Torrent Pharmaceuticals L | 177,632 | 81.8 | 9.67 | 27.4% |
| Apollo Hospitals Enter. L | 125,893 | 55.6 | 11.86 | 21.5% |
| Laurus Labs Limited | 125,380 | 93.6 | 20.73 | 18.3% |
| Zydus Lifesciences Ltd | 118,693 | 26.2 | 4.27 | 21.2% |
Which Mutual Funds Hold Supriya Lifescience Ltd?
Frequently Asked Questions about Supriya Lifescience Ltd
Supriya Lifescience Ltd (SUPRIYA) closed at ₹625.0 on NSE on 19 November 2026, up 10.2 (1.66%) from the previous close.
Supriya Lifescience Ltd trades on the NSE (National Stock Exchange of India) under the symbol SUPRIYA.
Supriya Lifescience Ltd has a TopFund Quality Score of 60/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Supriya Lifescience Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.